Corrigendum to “N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression”[Eur. J. Med. Chem. 2020 Jan 1;185:111725] (European Journal of Medicinal Chemistry (2020) 185, (S0223523419308773), (10.1016/j.ejmech.2019.111725))

Samir Mehndiratta, Mei Hsiang Lin, Yi Wen Wu, Chun Han Chen, Tung Yun Wu, Kuo Hsiang Chuang, Min Wu Chao, Yi Ying Chen, Shiow Lin Pan, Mei Chuan Chen, Jing Ping Liou

研究成果: 雜誌貢獻評論/辯論

摘要

The authors regret that the information of the second corresponding author (M.-C. Chen) in the affiliation and the footnote of pdf version was misplaced. The correct version should be: Mei-Chuan Chena,h∗∗ h Ph.D. Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taiwan. ∗∗Corresponding author. Ph.D. Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taiwan. The authors would like to apologise for any inconvenience caused
原文英語
文章編號112406
期刊European Journal of Medicinal Chemistry
199
DOIs
出版狀態已發佈 - 八月 1 2020

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

指紋 深入研究「Corrigendum to “N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression”[Eur. J. Med. Chem. 2020 Jan 1;185:111725] (European Journal of Medicinal Chemistry (2020) 185, (S0223523419308773), (10.1016/j.ejmech.2019.111725))」主題。共同形成了獨特的指紋。

  • 引用此